The Korea Health Industry Development Institute (KHIDI) said it is now accepting applications for its 2025 Pharmaceutical Industry Global Expansion Consulting Support Program. Korean small and medium-sized pharmaceutical and biotech companies interested in global market entry can apply until March 17.

KHIDI is accepting applications until March 17 for its 2025 Pharmaceutical Industry Global Expansion Consulting Support Program, offering up to 50 million won in subsidies to help Korean pharmaceutical and biotech SMEs enter global markets through specialized consulting.
KHIDI is accepting applications until March 17 for its 2025 Pharmaceutical Industry Global Expansion Consulting Support Program, offering up to 50 million won in subsidies to help Korean pharmaceutical and biotech SMEs enter global markets through specialized consulting.

The program provides financial assistance for consulting services to companies forming a consortium with specialized consulting agencies. The support is aimed at facilitating entry into major global markets such as the U.S. and Europe. Eligible consulting areas include global new drug development planning, clinical trials, regulatory approval, investment and licensing, corporate establishment, manufacturing, and contract manufacturing. Each project can receive up to 50 million won ($34,244) in government subsidies.

KHIDI offers preferential consideration for companies that hold Innovative Pharmaceutical Company certification, have previously participated in KHIDI’s global expansion programs, are residents of the Boston C&D Incubation Office, or possess Health New Technology (NET) certification.

The program also supports companies involved in KHIDI’s global expansion initiatives, including the overseas market development support program (BIO Europe, CPHI SEA) and companies selected for the Global Open Innovation Program pitching events. This includes industry partnerships such as Amgen Golden Ticket, AstraZeneca K-Bio Expressway, Novo Nordisk Partnering Day, and Takeda’s Acceleration Program.

"KHIDI provides comprehensive consulting support throughout the entire pharmaceutical and biopharmaceutical lifecycle, from basic consulting by our resident U.S. regulatory science experts to specialized consulting through Global Pharmaceutical Key Opinion Leaders (GPKOLs) and advisory groups,” said Kim Yong-woo, director of the Biopharmaceutical Industry Division at KHIDI. “The in-depth consulting offered through this program is tailored to each company’s specific needs."

Given the diverse needs and circumstances of companies preparing for global expansion, KHIDI encourages companies to take full advantage of its consulting support programs, Kim added.

For more details about KHIDI’s global expansion consulting support initiatives, KHIDI advised companies to visit its portal.

Related articles

Copyright © KBR Unauthorized reproduction, redistribution prohibited